Long‐term outcome of immunologic autograft engineering

Our phase III trial reported that autograft‐absolute lymphocyte count (A‐ALC) improved survival post‐autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) for a short‐term follow‐up of 2 years. We evaluated retrospectively in our phase III trial patients that the A‐ALC still...

Descripción completa

Detalles Bibliográficos
Autores principales: Porrata, Luis F., Inwards, David J., Ansell, Stephen M., Micallef, Ivana N., Johnston, Patrick B., Villasboas, Jose C., Paludo, Jonas, Markovic, Svetomir N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176079/
https://www.ncbi.nlm.nih.gov/pubmed/35846064
http://dx.doi.org/10.1002/jha2.404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176079/
https://www.ncbi.nlm.nih.gov/pubmed/35846064
http://dx.doi.org/10.1002/jha2.404

Ejemplares similares